Sponsored company news and issuer-paid coverage. Wall Street Wire articles are paid promotional content; see each article’s disclaimer.
In a market crowded with early-stage medical device companies promising incremental improvements, Inspira Technologies (NASDAQ: IINN) stands out for a different reason. Rather than focusing on a single product or narrow clinical indication, the company is building toward a broader vision: a blood-based intelligence platform spanning respiratory support,
Newly announced expanded OPKO partnership set to advance oral hypoparathyroidism treatment candidate toward the clinic, adding momentum to a pipeline already approaching Phase 3 in osteoporosis
With fiber installation costs hitting $77,000 per home in some federally funded rural deployments, this microcap’s hybrid technology could help carriers connect far more households with the same grant money.
Purple Biotech’s CAPTN-3 platform uses conditionally activated tri-specific antibody technology, part of a broader class of multispecific antibodies that has commanded $700 million+ upfront payments and multi-billion-dollar transactions across the pharmaceutical industry – yet the company trades at a single-digit-million valuation (NASDAQ: PPBT). For
Modern medicine has gotten remarkably good at developing drugs that work – and far less consistent at ensuring they’re used quickly and correctly in the real world. Needle fear remains a quiet but persistent barrier, especially in children, and it’s rarely treated as a design constraint. In preventive care,
For the biggest drug companies in the world, the holy grail in cancer treatment isn’t just shrinking tumors – it’s keeping them from coming back. Right now, the most commercially successful targeted lung cancer drugs on the market include a pill called Tagrisso. The therapy generates more than $6
As investors look for new areas of growth in healthcare, women’s health has become a rising theme. One of the biggest and least discussed conditions in this space is osteoporosis, a disease that weakens bones and affects an estimated 200 million women worldwide. It leads to fractures, hospital visits,
The cannabis industry may be approaching a pivotal regulatory moment. Major U.S. media outlets have reported that President Trump is considering an executive order that would direct federal agencies to pursue reclassifying cannabis from Schedule I to Schedule III. If implemented, such a move would represent the most significant
As burn injuries rise from combat, disasters, and industrial accidents, one company’s enzymatic product has become so effective that the U.S. government is buying and stockpiling it for national emergencies. MediWound (Nasdaq: MDWD) isn’t your typical biotech. Its product NexoBrid, an FDA-approved burn treatment, can clear
Past winners like Nalu Medical, BigHat, and Syncell later advanced to major partnerships and M&A deals. PolyPid’s (NASDAQ: PYPD) Phase 3 results now place it on similar footing
The Bottom Line: GLP-1 medicines reshaped obesity care by offering a biological alternative to surgery. MediWound (NASDAQ: MDWD) is applying that same idea to wound care. Its enzyme-based treatments can remove dead tissue without surgery, with NexoBrid® already approved in 40+ locations around the globe and EscharEx® showing
Antibiotic resistance may be creating one of the biggest crises and opportunities, in modern medicine, and companies like BiomX (NYSE:PHGE) could be sitting at the center of the solution. Using precision-engineered viruses known as phages to hunt down antibiotic-resistant bacteria, BiomX is advancing next-generation therapies for
